SCHEMBL16739383

SCHEMBL16739383

CN(C)c1ccc2cc(-c3ccc(F)cc3)c(N)nc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 4/20 0.50
▸ TERT O14746 1/20 0.50
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ TCF4 P15884 1/20 0.42
▸ CTNNB1 P35222 1/20 0.42
▸ PSMB5 P28074 2/20 0.40
▸ PGR P06401 1/20 0.40
▸ APAF1 O14727 1/20 0.40
▸ ADK P55263 1/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ FYN P06241 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18227142 0.88 APP (0.50) APPTERTMEN1KMT2ANPC1
SCHEMBL18226916 0.86 APP (0.47) APPTERTMEN1KMT2ANPC1
SCHEMBL18227091 0.85 TERT (0.50) APPTERTMEN1KMT2ANPC1
SCHEMBL16739384 0.85 TERT (0.46) APPTERTMEN1KMT2ANPC1
SCHEMBL18226918 0.83 APP (0.47) APPTERTTCF4CTNNB1PSMB5
SCHEMBL18227090 0.83 APP (0.47) APPTERTMEN1KMT2ANPC1
SCHEMBL24800995 0.79 TERT (0.50) APPTERTMEN1KMT2ANPC1
SCHEMBL22521398 0.78 NPC1 (0.46) MEN1KMT2ANPC1RAB9AFGFR1
SCHEMBL22521627 0.78 MEN1 (0.46) MEN1KMT2ANPC1RAB9AFGFR1
SCHEMBL16739391 0.78 TERT (0.49) APPTERTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9873670-B2 Arylquinoline and analog compounds and use thereof to treat cancer UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2018-01-23 — — US claimed
US-20160280652-A1 ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2016-09-29 — — US claimed
WO-2015077550-A1 ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2015-05-28 — — WO claimed
US-9873670-B2 Arylquinoline and analog compounds and use thereof to treat cancer UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2018-01-23 — — US disclosed
US-20160280652-A1 ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2016-09-29 — — US disclosed
WO-2015077550-A1 ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2015-05-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280652-A1 ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER CASP4, BAD, BID APP 1086/4885TERT 971/4885MEN1 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback